3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
40
Terminated
13
Recruiting
13
Unknown
12
Active not recruiting
7
Not yet recruiting
3
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Squamous Cell Carcinoma of Head and Neck
14
Head and Neck Neoplasms
12
Lung Neoplasms
10
Uterine Cervical Neoplasms
9
Neoplasms
9
Cholangiocarcinoma
5
Carcinoma, Squamous Cell
5
Carcinoma
5
Mesothelioma, Malignant
4
Carcinoma, Hepatocellular
4
Tongue Neoplasms
3
Small Cell Lung Carcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Oropharyngeal Neoplasms
3
Mouth Neoplasms
3
Laryngeal Neoplasms
3
Hypopharyngeal Neoplasms
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Nasopharyngeal Neoplasms
2
Mesothelioma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Interventions
Radiosurgery
7
Oxaliplatin
7
Docetaxel
7
Paclitaxel
5
Fluorouracil
5
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Carboplatin
4
Capecitabine
4
Trastuzumab
3
Radiotherapy
3
Radiation
3
Leucovorin
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
Cetuximab
3
Bevacizumab
3
spartalizumab
2
sipuleucel-T
2
repotrectinib
2
pembrolizumab
2
pazopanib
2
orteronel
2
fludarabine
2
atezolizumab
2
aldesleukin
2
Temozolomide
2
Surveys and Questionnaires
2
Sunitinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasm Metastasis
×
Cisplatin
×
Clear all
NCT05948462
2023-12-13
NSCLC
SCRI Development Innovations, LLC
Phase 2
Withdrawn